<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35642868</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>Anti-phosphatidylserine/prothrombin antibodies and thrombosis associate positively with HLA-DRB1*13 and negatively with HLA-DRB1*03 in SLE.</ArticleTitle><Pagination><StartPage>924</StartPage><EndPage>933</EndPage><MedlinePgn>924-933</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keac327</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Emerging evidence demonstrates that aPS-PT associate with thrombotic events. Genetic predisposition, including HLA-DRB1 alleles, is known to contribute to the occurrence of conventional aPL [anti-&#x3b2;2glycoprotein-I (anti-&#x3b2;2GPI) and aCL]. We investigated associations between aPS-PT and HLA-DRB1* alleles and thrombosis in SLE. Conventional aPL were included for comparison.</AbstractText><AbstractText Label="METHODS">We included 341 consecutive SLE patients, with information on general cardiovascular risk factors, including blood lipids, LA and thrombotic events. aPS/PT, anti-&#x3b2;2GPI and aCL of IgA/G/M isotypes and LA were quantified.</AbstractText><AbstractText Label="RESULTS">aPS/PT antibodies associated positively with HLA-DRB1*13 [odds ratio (OR) 2.7, P&#x2009;=&#x2009;0.002], whereas anti-&#x3b2;2GPI and aCL antibodies associated primarily with HLA-DRB1*04 (OR 2.5, P&#x2009;=&#x2009;0.0005). These associations remained after adjustment for age, gender and other HLA-DRB1* alleles. HLA-DRB1*13, but not DRB1*04, remained as an independent risk factor for thrombosis and APS after adjustment for aPL and cardiovascular risk factors. The association between DRB1*13 and thrombosis was mediated by aPS-PT positivity. HLA-DRB1*03, on the other hand, associated negatively with thrombotic events as well as all aPL using both uni- and multivariate analyses. HLA-DRB1*03 had a thrombo-protective effect in aPL-positive patients. Additionally, HLA-DRB1*03 was associated with a favourable lipid profile regarding high-density lipoprotein and triglycerides.</AbstractText><AbstractText Label="CONCLUSIONS">HLA-DRB1*13 confers risk for both aPS-PT and thrombotic events in lupus. The association between HLA-DRB1*13 and thrombosis is largely, but not totally, mediated through aPS-PT. HLA-DRB1*03 was negatively associated with aPL and positively with favourable lipid levels. Thus, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elbagir</LastName><ForeName>Sahwa</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2515-7066</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Gallo</LastName><ForeName>Lina-Marcela</ForeName><Initials>LM</Initials><Identifier Source="ORCID">0000-0002-5688-0102</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosso</LastName><ForeName>Giorgia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zickert</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunnarsson</LastName><ForeName>Iva</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahler</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Research and Development, Werfen Autoimmunity, San Diego, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenungsson</LastName><ForeName>Elisabet</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-3396-3244</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>R&#xf6;nnelid</LastName><ForeName>Johan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1186-3226</Identifier><AffiliationInfo><Affiliation>Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017152">Antibodies, Antiphospholipid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-26-7</RegistryNumber><NameOfSubstance UI="D011516">Prothrombin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010718">Phosphatidylserines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053482">beta 2-Glycoprotein I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017152" MajorTopicYN="N">Antibodies, Antiphospholipid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011516" MajorTopicYN="N">Prothrombin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010718" MajorTopicYN="N">Phosphatidylserines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053482" MajorTopicYN="N">beta 2-Glycoprotein I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA</Keyword><Keyword MajorTopicYN="N">SLE</Keyword><Keyword MajorTopicYN="N">aPL</Keyword><Keyword MajorTopicYN="N">antiphosphatidylserine/prothrombin</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>8</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35642868</ArticleId><ArticleId IdType="pmc">PMC9891424</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac327</ArticleId><ArticleId IdType="pii">6596595</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Willis R, Pierangeli SS.. Pathophysiology of the antiphospholipid antibody syndrome. Auto Immun Highlights 2011;2:35&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4389016</ArticleId><ArticleId IdType="pubmed">26000118</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano A, Galeazzi M, Sebastiani GD.. Antiphospholipid syndrome's genetic and epigenetic aspects. Autoimmun Rev 2019;18:102352.</Citation><ArticleIdList><ArticleId IdType="pubmed">31323355</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagenais P, Urowitz MB, Gladman DD, Norman CS.. A family study of the antiphospholipid syndrome associated with other autoimmune diseases. J Rheumatol 1992;19:1393&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1433007</ArticleId></ArticleIdList></Reference><Reference><Citation>May KP, West SG, Moulds J, Kotzin BL.. Different manifestations of the antiphospholipid antibody syndrome in a family with systemic lupus erythematosus. Arthritis Rheum 1993;36:528&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8457227</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya S, Kendra J, Schiach C.. A case study of familial anti-phospholipid syndrome. Clin Lab Haematol 2002;24:313&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12358894</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung K, Coldewey R, Corvetta A. et al. MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. SLE Study Group. Autoimmunity 1992;13:95&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1467439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein R, Moulds JM, Smith CD, Sengar DP.. MHC studies of the primary antiphospholipid antibody syndrome and of antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 1996;23:1173&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8823688</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeazzi M, Sebastiani GD, Tincani A. et al. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000;9:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10715100</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliz R, Atsumi T, Kondeatis E. et al. HLA class II gene polymorphisms in antiphospholipid syndrome: haplotype analysis in 83 Caucasoid patients. Rheumatology (Oxford) 2001;40:31&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11157139</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh NJ, Maddison PJ.. HLA-DR antigens and anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1989;32:1623&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">2597215</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil HP, Gavaghan TP, Krilis SA, Geczy AF, Chesterman CN.. HLA-DR antigens and anticardiolipin antibodies. Clin Exp Rheumatol 1990;8:425&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2397631</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnett FC, Thiagarajan P, Ahn C, Reveille JD.. Associations of anti-beta2-glycoprotein I autoantibodies with HLA class II alleles in three ethnic groups. Arthritis Rheum 1999;42:268&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025920</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachenko O, Lapin S, Maslyansky A. et al. Influence of HLA-DRB1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in European part of Russia. Autoimmun Rev 2019;18:558&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30844554</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstr&#xf6;m E, Gustafsson JT, J&#xf6;nsen A. et al. HLA-DRB104/13 alleles are associated with vascular disease and antiphospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 2013;72:1018&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22893315</ArticleId></ArticleIdList></Reference><Reference><Citation>Murali V, Rathika C, Ramgopal S. et al. Susceptible and protective associations of HLA DRB1/DQB1 alleles and haplotypes with ischaemic stroke. Int J Immunogenet 2016;43:159&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">27105925</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Murru V. et al. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014;111:354&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24172938</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Foddai SG, Cecchi I. et al. Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost 2020;120:592&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32185783</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbagir S, Grosso G, Mohammed NA. et al. Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. Lupus 2021;30:1289&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8209767</ArticleId><ArticleId IdType="pubmed">33957795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan EM, Cohen AS, Fries JF. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7138600</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbagir S, Elshafie AI, Elagib EM. et al. Sudanese and Swedish patients with systemic lupus erythematosus: immunological and clinical comparisons. Rheumatology (Oxford) 2020;59:968&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188463</ArticleId><ArticleId IdType="pubmed">31411331</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbagir S, Elshafie AI, Elagib EM. et al. High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients. Lupus 2020;29:1412&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536526</ArticleId><ArticleId IdType="pubmed">32741301</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Sanna G, Murru V. et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford) 2013;52:1397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">23315788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Ramirez C. et al. Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmun Rev 2020;19:102641.</Citation><ArticleIdList><ArticleId IdType="pubmed">32801044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadley Wickham MA, Bryan J, Chang W. et al. Welcome to the tidyverse. Open Source Softw 2019;4:1686.</Citation></Reference><Reference><Citation>Rosseel Y. lavaan: an {R} package for structural equation modeling. J Stat Softw 2012;48:1&#x2013;36.</Citation></Reference><Reference><Citation>Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R package for causal mediation analysis. J Stat Softw 2014;59:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertolaccini ML, Atsumi T, Caliz AR. et al. Association of antiphosphatidylserine/prothrombin autoantibodies with HLA class II genes. Arthritis Rheum 2000;43:683&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728763</ArticleId></ArticleIdList></Reference><Reference><Citation>Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GR.. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992;35:124&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">1731810</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerhardsson J, Sundelin B, Zickert A. et al. Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther 2015;17:109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4443508</ArticleId><ArticleId IdType="pubmed">25927214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitany A, Tarr T, Gyetvai A. et al. Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome. Ann N Y Acad Sci 2009;1173:545&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">19758197</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas MV, da Silva LM, Deghaide NH, Donadi EA, Louzada-J&#xfa;nior P.. Is HLA class II susceptibility to primary antiphospholipid syndrome different from susceptibility to secondary antiphospholipid syndrome? Lupus 2004;13:125&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14995006</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Moulds JM, Ahn C. et al.; the Lumina Study Group. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998;41:1161&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RG, Harley JB, Bias WB. et al. Two Ro (SS-A) autoantibody responses in systemic lupus erythematosus. Correlation of HLA-DR/DQ specificities with quantitative expression of Ro (SS-A) autoantibody. Arthritis Rheum 1988;31:496&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">2451920</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudek NL, Maier S, Chen ZJ. et al. T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB10301/DQB10201. Arthritis Rheum 2007;56:3387&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">17907193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hom G, Graham RR, Modrek B. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008;358:900&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204098</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Gallo LM, Oke V, Lundstr&#xf6;m E. et al. Four systemic lupus erythematosus subgroups, defined by autoantibodies status, differ regarding HLA-DRB1 genotype associations and immunological and clinical manifestations. ACR Open Rheumatol 2022;4:27&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8754019</ArticleId><ArticleId IdType="pubmed">34658170</ArticleId></ArticleIdList></Reference><Reference><Citation>Giger JN, Strickland OL, Weaver M, Taylor H, Acton RT.. Genetic predictors of coronary heart disease risk factors in premenopausal African-American women. Ethn Dis 2005;15:221&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">15825968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovalev Yu P, Dzeranova N, Serova LD. et al. Comparison of HLA antigen spectrum in atherosclerosis of various localization. Cor Vasa 1990;32:118&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2350965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori N, Kuwana M, Kaburaki J. et al. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000;43:65&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">10643701</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Yoshida K, Kaburaki J. et al. Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood 2001;98:1889&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">11535526</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwana M. Beta2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity. Thromb Res 2004;114:347&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">15507264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani GD, Galeazzi M, Morozzi G, Marcolongo R.. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum 1996;25:414&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8792513</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Tsutsumi A, Ohnishi Y. et al. T cell epitopes of prothrombin in patients with antiphospholipid syndrome. Ann Rheum Dis 2003;62:905&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1754661</ArticleId><ArticleId IdType="pubmed">12922970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>